Latest News and Press Releases
Want to stay updated on the latest news?
-
New York, July 30, 2025 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA), leader and innovator of the largest global gathering of the neuromuscular disease community, announced today...
-
NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- via InvestorWire — Calidi Biotherapeutics Inc. (NYSE American: CLDI) today announces its placement in an editorial published by NetworkNewsWire ("NNW"),...
-
NEW YORK, July 08, 2025 (GLOBE NEWSWIRE) -- via InvestorWire — Calidi Biotherapeutics Inc. (NYSE American: CLDI) today announces its placement in an editorial published by NetworkNewsWire ("NNW"),...
-
Lexeo Therapeutics Announces FDA Breakthrough Therapy Designation for LX2006 in Friedreich Ataxia
-
Lexeo Therapeutics, Perceptive Xontogeny Venture Funds and venBio Partners Announce Partnership to Advance Novel Cardiac RNA Therapeutics
-
Lexeo Therapeutics Announces $80 Million Equity Financing to Further Advance Development of Transformative Genetic Medicines for Cardiovascular Diseases
-
Les données montrent les avantages d'un vecteur HSV-1 non réplicatif (nrHSV-1) unique intégrant deux transgènes présentant des cinétiques d'expression indépendantes.Ces vecteurs transduisent...
-
Data highlights advantages of single, non-replicative HSV-1 (nrHSV-1) vector hosting two transgenes with independent expression kineticsVectors also show high transduction rate of neurons in the CNS...
-
Lexeo Therapeutics Reports First Quarter 2025 Financial Results and Operational Highlights
-
Lexeo Therapeutics Announces Positive Interim Phase 1/2 Data for LX2006 in Friedreich Ataxia Cardiomyopathy Supporting Advancement to Registrational Study